In Ghana, a generation of hard-won progress against childhood disease now rests on uncertain ground. The suspension of USAID programmes has opened a $156 million gap in the country's health financing, placing at risk the very infrastructure — cold chains, outreach workers, defaulter tracing — that transformed a malaria vaccine into a 13 percent reduction in child mortality. The crisis arrives at a moment when Ghana was already navigating a planned transition toward full self-financing of its immunisation programme by 2030, compressing what was meant to be a gradual handover into something far
US Aid Cuts Jeopardize Ghana's Hard-Won Immunisation Gains
Potential loss of life-saving immunisation protection for children in remote communities, with particular risk in hard-to-reach regions where vaccine coverage could decline.
A child should not lose protection against a preventable disease because of a financing problem
Mark
So Ghana had actually solved the hard part—they got the malaria vaccine working and cut child deaths by 13 percent. What went wrong?
Mimi
The vaccine itself didn't go anywhere. But keeping it in arms requires a whole system: workers traveling to villages, tracking kids who miss doses, maintaining refrigeration equipment, organizing outreach. When USAID funding stopped, that system started breaking down.
Luke
How much of the health system actually depends on USAID? Is this a total collapse or a significant strain?
Mimi
It's significant. The $78.2 million health shortfall is real, but Ghana's health budget is larger than that. The problem is that USAID money was funding specific operational costs—fuel for transport, cold-chain maintenance, outreach staff. Those aren't easy to replace quickly.
Mark
The reporting mentions that 75 percent of districts in northern Ghana reported vaccine delays. That's a lot of disruption.
Mimi
Yes, and it matters most in places like the Oti Region, where communities are remote and hard to reach. A 2025 study found vaccine coverage there was actually quite good—85 percent. But that's because the system was working. If funding pressures erode the outreach capacity, that number will drop.
Luke
But the story also quotes officials saying this is an opportunity to reduce donor dependence. Is that realistic, or is that just spin?
Mimi
Both, probably. A government official and civil society leaders genuinely believe Ghana should build more domestic funding capacity. That's not wrong. But it doesn't solve the immediate problem—you can't instantly replace operational funding with local fundraising or private investment.
Mark
What about the private sector stepping in? The hospitals mentioned in the story seem interested.
Mimi
They're interested in medical tourism and specialized care, which is a different market. Routine immunization in remote villages doesn't generate revenue. Private hospitals can't replace public health infrastructure.
Luke
So what's the actual timeline here? When does Ghana need to have this figured out?
Mimi
Immediately, for the vaccine delays. But also by 2030, when Ghana is supposed to take full responsibility for its immunization program from Gavi. That's a lot of pressure at once.
Mark
Is there any indication Ghana will actually meet that 2030 deadline?
Mimi
The story mentions they've removed caps on National Health Insurance Scheme funding and are backing local vaccine manufacturing. Those are real steps, but they take time. The reporting doesn't suggest Ghana is on track—it raises the question of whether any country can build that independence fast enough.
The Pulse
- A $78.2 million health funding shortfall has left Ghana's immunisation machinery — cold-chain equipment, transport fuel, outreach campaigns — beginning to break down in real time.
- In northern Ghana, three-quarters of surveyed districts have already reported vaccine delays or irregular supplies, signaling that the damage is not hypothetical but measurable and spreading.
- The Oti Region, which had achieved 85.3 percent basic antigen coverage well above the national average, now faces the particular risk of losing gains in communities that are hardest to reach and most dependent on organized outreach.
- Officials and civil society are proposing alternatives — medical tourism, corporate partnerships, local NGO funding — but none of these can quickly replicate the public infrastructure needed to find and vaccinate children in remote villages.
- Ghana faces a double pressure: the immediate shock of US funding withdrawal and a pre-existing deadline to assume full immunisation financing by 2030 as Gavi support winds down, leaving little room to absorb either disruption alone.
In Ghana, a generation of hard-won progress against childhood disease now rests on uncertain ground. The suspension of USAID programmes has opened a $156 million gap in the country's health financing, placing at risk the very infrastructure — cold chains, outreach workers, defaulter tracing — that transformed a malaria vaccine into a 13 percent reduction in child mortality. The crisis arrives at a moment when Ghana was already navigating a planned transition toward full self-financing of its immunisation programme by 2030, compressing what was meant to be a gradual handover into something far more urgent. What hangs in the balance is not merely a funding line, but the question of whether a child in a remote village will receive the protection that science and years of effort made possible.
Ghana had built something worth protecting. Years of international partnership had woven the RTS,S malaria vaccine into the country's routine immunisation programme, and the results were measurable — a 13 percent reduction in child mortality among vaccinated children, roughly one in eight deaths averted. But the vaccine was only the visible part. The real architecture was human and logistical: health workers traveling to remote villages, cold-chain equipment keeping doses viable, systems designed to track down children who had missed their shots.
When USAID suspended its programmes, that architecture lost its financial foundation. Ghana faced a $156 million gap across affected health initiatives, with $78.2 million directly tied to health services including malaria prevention, maternal care, nutrition, and HIV treatment. The effects were swift. Studies in northern Ghana found that three-quarters of surveyed districts reported vaccine delays or irregular supplies. Equipment broke down. Fuel ran out. The infrastructure that had made mortality reductions possible began to fray at its edges.
In the Oti Region, where rural communities had achieved 85.3 percent basic antigen coverage — far above the national average of 62.1 percent — local health officials spoke plainly about what was at stake. Mark Appiah, chairman of the regional health committee, warned that funding pressure could erode outreach, transportation, supervision, and defaulter tracing all at once. "A child should not lose protection against a preventable disease because the health system is experiencing a financing problem," he said.
Some officials framed the crisis as a catalyst. A government source argued the USAID withdrawal was an opportunity to reduce dependence on Western donors and mobilize domestic resources. Health directors proposed expanding medical tourism and diagnostic capacity. Private hospitals signaled readiness to grow their role. Civil society organizations offered to channel corporate support into the gaps.
Yet none of these alternatives could quickly replace what public health infrastructure does in practice — reaching the most remote children, maintaining cold chains, running the systems that find families who fall through the cracks. Ghana also faced a longer-term reckoning: the country was already on an accelerated path to assume full immunisation financing by 2030 as Gavi support wound down, a transition that now had to absorb an immediate shock it was not designed to handle.
For families like Rahinatu's in northern Ghana, the hope was simply that government would find a homegrown solution before the gaps became permanent. The question Ghana now shares with many countries watching from similar positions is whether financial independence can be built fast enough to protect the children who depend on these services today.
Ghana had built something remarkable. Years of effort and international partnership had brought the RTS,S malaria vaccine into the country's routine immunisation programme, and the numbers proved it worked—a 13 percent reduction in child mortality among vaccinated children, which meant roughly one in eight deaths averted. The vaccine itself was only part of the story. The real work happened in the field: health workers traveling to remote villages, tracking down children who missed doses, maintaining the cold-chain equipment that keeps vaccines viable, organizing outreach campaigns in communities scattered across difficult terrain.
Then the funding stopped. When the United States Agency for International Development suspended its programmes in Ghana, the country faced a $156 million funding gap across all affected health initiatives. Of that, $78.2 million was earmarked for health services—malaria prevention, maternal and child care, nutrition, family planning, and HIV treatment. The money that had kept the machinery running simply vanished.
The immediate consequence was visible in the data. A study of donor withdrawal in northern Ghana found that three-quarters of the districts surveyed reported vaccine delays or irregular supplies. Cold-chain equipment broke down without replacement funds. Delivery kits sat unused. Transport fuel ran out. The infrastructure that had made those mortality reductions possible began to fray.
In the Oti Region, where many communities are rural and difficult to reach, the stakes felt particularly high. A 2025 study had found that basic antigen coverage there stood at 85.3 percent—well above the national schedule average of 62.1 percent. Mark Appiah, chairman of the Oti Regional Health Committee, was blunt about what the funding pressure could do: "Funding pressures could affect outreach, defaulter tracing, transportation, supervision and immunisation campaigns, all of which are essential to maintaining these gains." He called for a structured approach to domestic resource mobilization and partnerships with businesses and NGOs, but acknowledged the immediate challenge. "A child should not lose protection against a preventable disease because the health system is experiencing a financing problem."
Some officials saw the crisis as an opportunity to rethink Ghana's dependence on Western donors. A government official, speaking anonymously, argued that the USAID cut was "a perfect opportunity for us to put our house in order and utilise our resources to take care of our citizens." Nana Owusu Ensaw, municipal director of health for Akuapim North, proposed that Ghana use the shock to develop medical tourism, attracting patients from across West Africa and the diaspora while building diagnostic and telemedicine capacity. Private hospitals like Banahene Specialist Hospital signaled readiness to expand their role. Civil society organizations, including the Humserve Africa Foundation, said they could fill gaps through locally generated funding and corporate support.
But private investment and local fundraising could not immediately replace the public health infrastructure needed to reach children in remote villages. The cold-chain equipment still had to work. The health workers still had to travel. The defaulter tracing systems still had to function. These were not services that could be quickly privatized or crowdfunded.
Ghana's longer-term challenge was even more complex. The country was already in an accelerated transition away from Gavi, the Vaccine Alliance, and was expected to assume full financing responsibility for its immunisation programme by 2030. Gavi itself was facing funding pressures and pushing member countries to increase domestic contributions. Ghana had begun responding—removing caps on funding from the National Health Insurance Scheme and backing efforts to develop local vaccine manufacturing capacity—but these changes would take time.
Rahinatu, a mother in northern Ghana whose child had benefited from routine immunisation, expressed what many families in vulnerable communities felt: concern about the immediate disruption, but hope that "the government will figure a homegrown solution as soon as possible." Her optimism was understandable but untested. Ghana now faced pressure from two directions at once: the immediate disruption caused by the withdrawal of US funding, and the longer-term need to take on a greater share of immunisation costs as Gavi support wound down. The question facing Ghana—and many other countries watching from similar positions—was whether governments could build financial independence fast enough without allowing the health services that children relied on today to weaken in the process.
Notable Quotes
Funding pressures could affect outreach, defaulter tracing, transportation, supervision and immunisation campaigns, all of which are essential to maintaining these gains.— Mark Appiah, chairman of the Oti Regional Health Committee
We have always used internally generated funding from colleagues and corporate Ghana to support all health interventions. We believe that civil society organisations can step in and fill the gap that the USAID cuts are creating.— George Kwame Egeh, cofounder and director of operations at the Humserve Africa Foundation
Want the full story?
Read the original at Al Jazeera ↗
Health & Medicine